唾液CD44与总蛋白水平检测用于发现口腔癌和口咽癌复发风险:一项非随机临床试验
这项多机构非随机临床试验纳入172例新诊断的口腔癌和口咽癌患者,在治疗前及治疗后3、6、12、18个月采集漱口液检测唾液CD44和总蛋白水平,并随访3年。酶联免疫吸附试验检测显示,CD44和总蛋白水平升高与复发风险增加相关;快速床旁检测有一定前景,但尚需进一步开发。
要点
- 多机构非随机临床试验纳入172例新诊断口腔癌和口咽癌患者。
- 多变量校正分析中,CD44和总蛋白水平升高与复发风险增加相关。
- 床旁快速检测有一定前景,但尚需进一步开发用于该适应证。
核心结论
- 治疗后纵向监测唾液CD44和总蛋白水平升高,可识别未来癌症复发风险增加的患者。
- CD44和总蛋白快速床旁检测有一定前景,但尚需进一步开发用于该适应证。
研究设计与样本
- 多机构非随机临床试验,评估一种新型诊断/筛查检测方法。
- 研究地点包括加州大学圣地亚哥分校、约翰斯·霍普金斯大学、大巴尔的摩医学中心、纽约大学和圣地亚哥退伍军人事务医院。
- 纳入新近活检证实、未经治疗的口腔癌和口咽癌患者,2017年4月至2019年4月入组。
- 于治疗前基线及治疗完成后3、6、12、18个月采集漱口液,随后随访3年确定疾病状态。
- 入组172例患者,平均(SD)年龄62.5(10.2)岁,122例(70.9%)为男性。
主要发现
- 172例中92例(53.3%)从不吸烟,99例(57.6%)曾或现饮酒,113例(65.7%)为口咽癌,其中95例(84.1%)人乳头瘤病毒阳性。
- 基线时肿瘤部位与检测结果相关:口腔癌患者基线床旁检测阳性率为47/51(92.2%),口咽癌患者为85/110(77.3%)。
- 以CD44或总蛋白水平为时间变化协变量的Cox回归中,较高CD44水平与较高复发风险有统计学显著关联(风险比1.06,95%CI 1.00-1.12),总蛋白水平未达统计学显著。
- 多变量校正分析中,较高CD44和总蛋白水平与复发风险比增加相关,分别为1.13(95%CI 1.04-1.22)和3.51(95%CI 1.24-9.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- CD44和总蛋白快速床旁检测尚需进一步开发用于该适应证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Oral and oropharyngeal cancer have low survival rates, and incidence continues to increase. OBJECTIVE: To determine whether soluble CD44 and total protein (TP) are useful for monitoring head and neck cancer recurrence, either used in a point-of-care (POC) test or as individual laboratory-based biomarkers. DESIGN, SETTING, AND PARTICIPANTS: This multi-institutional nonrandomized clinical trial testing a novel diagnostic/screening assay took place across the University of California, San Diego; Johns Hopkins University; the Greater Baltimore Medical Center; New York University; and the San Diego Veterans Affairs Hospital. Patients with newly biopsy-proven, untreated oral cavity and oropharyngeal cancer were enrolled. Patients were enrolled April 2017 to April 2019, and data were analyzed December 2022 to June 2023. EXPOSURE: POC salivary oral rinse test. MAIN OUTCOMES AND MEASURES: Oral rinses were collected at pretreatment baseline and 3, 6, 12, and 18 months after completion of therapy; participants were then followed up for 3 years to define disease status. Associations of baseline characteristics with a positive test were evaluated by Fisher exact test. The association of a positive value on the CD44 or TP test with progression-free survival was evaluated in an adjusted multivariable proportional hazards model. RESULTS: Of 172 patients enrolled, the mean (SD) age was 62.5 (10.2) years, and 122 (70.9%) identified as male. Additionally, 92 patients (53.3%) had never smoked, 99 (57.6%) formerly or currently drank alcohol, and 113 (65.7%) presented with oropharyngeal cancers, which were positive for human papillomavirus in 95 (84.1%). Tumor site was associated with test results at baseline; patients with oral cavity cancer had a higher baseline positive POC test rate (47 of 51 [92.2%]) compared to patients with oropharyngeal cancer (85 of 110 [77.3%]). Using Cox regression models with CD44 or TP level as a time-varying covariate, a higher CD44 level showed a statistically significant association with a higher hazard of recurrence (hazard ratio, 1.06; 95% CI, 1.00-1.12), though the TP level was not statistically significant. In multivariate adjusted analysis, higher CD44 and TP levels were associated with increased hazard ratios of recurrence of 1.13 (95% CI, 1.04-1.22) and 3.51 (95% CI, 1.24-9.98), respectively. CONCLUSION AND RELEVANCE: In this multi-institutional nonrandomized clinical trial of an assay, posttreatment longitudinal monitoring for elevated salivary CD44 and TP levels using an enzyme-linked immunosorbent assay-based laboratory test identified patients at increased risk of future cancer recurrence. The CD44 and TP rapid POC test holds some promise, but further development is needed for this indication. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03148665.
引用
- Franzmann EJ, Qi Y, Peifer S, et al. Salivary CD44 and Total Protein Levels to Detect Risk for Oral and Oropharyngeal Cancer Recurrence: A Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 39145961. doi:10.1001/jamaoto.2024.2490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。